I hereby bury that this paper (along with any paper referred to as being attached seed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA

Dated: January 5, 2007

Signature: (Shawn P. Foley)

Docket No.: FELDER 3.9-001 CONT DIV (PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Felder et al.

Application No.: 10/677,983

Group Art Unit: 1632

Filed: October 2, 2003

Examiner: A. M. Falk

For: G PROTEIN-RELATED KINASE MUTANTS

IN ESSENTIAL HYPERTENSION

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each reference was of record in Application No. 09/614,748, which was issued as U.S. patent 6,660,474, the benefit of which is claimed under \$120. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: January 5, 2007

Respectfully submitted,

Shawn P. Foley

Registration No.: 33,071 LERNER, DAVID, LITTENBERG,

KRUMHOLZ & MENTLIK, LLP 600 South Avenue West

Westfield, New Jersey 07090

(908) 654-5000

Attorney for Applicant

LD-459\

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0551-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE erwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 2 Sheet of

Complete if Known			
Application Number	10/677,983-Conf. #9056		
Filing Date	October 2, 2003		
First Named Inventor	Robin A. Felder		
Art Unit	1632		
Examiner Name	A. M. Falk		
Attorney Docket Number	FELDER 3.9-001 CONT DIV		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۳º	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>		
	CA	Elseth et al. Principles of Modern Genetics pp. 542-545 1994.	
	Casari et al. Hypertension 25(3):320-326 (1995).		
	CC	Virlon et al. Endocrinilogy 139(5):2784-2795 (1998).	
	CD	Courjault-Gautier et al., J. Am. Soc. Nephrol. 5:1949-1963 (1994).	1
	CE	Detrisac, et al., Kidney Int. 25:383-390 (1984).	
	CF	Jose et al., Pharmacol Ther 80:149-182 (1998).	
	CG	Ng et al., Eur. J. Pharmacol. 267:7-19 (1994).	
	СН	Premont, et al., FASEB J. 9:175-182 (1995).	
	CI	Palczewski, Protein Sci. 3:1355-1361 (1994).	
	CJ	Inglese, et al., J. Biol. Chem. 268:23735-23738 (1993).	
	CK	Gros, J. Clin. Invest. 99(9):2087-2093 (1997).	
	CL	Ambrose, et al., Hum. Mol. Genet. 1:697-703 (1993).	
	СМ	Sallese et al., Biochem. Biophys. Res. Commun. 199:848-854 (1994).	
	CN	Menard, et al., Biochemistry 35(13):4155-4160 (1996).	
	co	Loudon, et al., J. Biol. Chem. 272(43);27422-27427 (1997).	
	CP	Premont, et al., J. Biol. Chem. 271(11):6403-6410 (1996).	
	CQ	Albrecht, et al., J. Clin. Invest. 97(10):2283-2288 (1996).	
	CR	Ohbu, et al., American J. of Physiology 268:R231-R235 (1995).	
	cs	Eisner, et al., Am. J. Physiol. 273:R317-R323 (1997).	
	СТ	Jin, et al., Am. J. Physiol. 273:C1623-C1631 (1997).	
	CU	Woost, et al., Kidney International 50:125-134 (1996).	
	CV	Chen, et al., Kidney International 49:153-157 (1996).	
	CW	Racusen, et al., Kidney International 48:536-543 (1995).	
	CX	Ryan, et al., Kidney International 45:48-57 (1994).	

Examiner	-	Date	
Signature		Considered	

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ion Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known 10/677,983-Conf. #9056 Application Number **INFORMATION DISCLOSURE** Filing Date October 2, 2003 STATEMENT BY APPLICANT First Named Inventor Robin A. Felder 1632 Art Unit (Use as many sheets as necessary) Examiner Name A. M. Falk FELDER 3.9-001 CONT DIV 2 2 Sheet of Attorney Docket Number

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.